Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures

PLoS Med. 2023 Mar 6;20(3):e1004190. doi: 10.1371/journal.pmed.1004190. eCollection 2023 Mar.

Abstract

In an analysis of risk evaluation and mitigation strategies for teratogenic drugs, Ameet Sarpatwari, Beatrice Brown and Aaron Kesselheim explore the variation in primary and secondary prevention measures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Risk Evaluation and Mitigation*
  • Secondary Prevention
  • Teratogens* / toxicity

Substances

  • Teratogens